Summary of Treatment-Emergent Adverse Events (TEAEs)

Number (%) of Unique Subjects with ≥ 1 TEAE, by SOC and Preferred Term

Primary System Organ Class Reported Term for the Adverse Event	Placebo N = 86[†1]	Xanomeline High Dose N = 72[†1]	Xanomeline Low Dose N = 96[†1]	Total N = 254[†1]
Treatment Emergent AEs	*65 (76%)*	*68 (94%)*	*84 (88%)*	*217 (85%)*
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	**21 (24%)**	**36 (50%)**	**51 (53%)**	**108 (43%)**
APPLICATION SITE PRURITUS	6 (7%)	21 (29%)	23 (24%)	50 (20%)
APPLICATION SITE ERYTHEMA	3 (3%)	14 (19%)	13 (14%)	30 (12%)
APPLICATION SITE DERMATITIS	5 (6%)	7 (10%)	9 (9%)	21 (8%)
APPLICATION SITE IRRITATION	3 (3%)	9 (12%)	9 (9%)	21 (8%)
APPLICATION SITE VESICLES	1 (1%)	5 (7%)	5 (5%)	11 (4%)
FATIGUE	1 (1%)	5 (7%)	5 (5%)	11 (4%)
OEDEMA PERIPHERAL	2 (2%)	2 (3%)	1 (1%)	5 (2%)
APPLICATION SITE SWELLING	0 (0%)	2 (3%)	1 (1%)	3 (1%)
APPLICATION SITE URTICARIA	0 (0%)	1 (1%)	2 (2%)	3 (1%)
CHILLS	1 (1%)[†1]	1 (1%)[†1]	1 (1%)	3 (1%)[†1]
MALAISE	0 (0%)	2 (3%)	1 (1%)	3 (1%)
PYREXIA	2 (2%)	0 (0%)	1 (1%)	3 (1%)
APPLICATION SITE PAIN	0 (0%)	2 (3%)	0 (0%)	2 (1%)
APPLICATION SITE PERSPIRATION	0 (0%)	2 (3%)	0 (0%)	2 (1%)
APPLICATION SITE REACTION	1 (1%)	1 (1%)	0 (0%)	2 (1%)

[1] † Denominator = all subjects per arm in ADSL (safety population).

TEAE: Treatment-Emergent Adverse Event (TRTEMFL = 'Y'). A subject is counted once per SOC/PT even if multiple events were reported. SOCs and preferred terms sorted by descending overall frequency.

Summary of Treatment-Emergent Adverse Events (TEAEs)

Number (%) of Unique Subjects with ≥ 1 TEAE, by SOC and Preferred Term

Primary System Organ Class Reported Term for the Adverse Event	Placebo N = 86[†1]	Xanomeline High Dose N = 72[†1]	Xanomeline Low Dose N = 96[†1]	Total N = 254[†1]
ASTHENIA	1 (1%)	0 (0%)	1 (1%)	2 (1%)
CHEST DISCOMFORT	0 (0%)	1 (1%)	1 (1%)	2 (1%)
CHEST PAIN	0 (0%)	2 (3%)	0 (0%)	2 (1%)
OEDEMA	0 (0%)	0 (0%)	2 (2%)	2 (1%)
PAIN	0 (0%)	1 (1%)	1 (1%)	2 (1%)
APPLICATION SITE BLEEDING	0 (0%)	0 (0%)	1 (1%)	1 (0%)
APPLICATION SITE DESQUAMATION	0 (0%)	0 (0%)	1 (1%)	1 (0%)
APPLICATION SITE DISCHARGE	0 (0%)	1 (1%)	0 (0%)	1 (0%)
APPLICATION SITE DISCOLOURATION	0 (0%)	0 (0%)	1 (1%)	1 (0%)
APPLICATION SITE INDURATION	1 (1%)	0 (0%)	0 (0%)	1 (0%)
APPLICATION SITE WARMTH	0 (0%)	0 (0%)	1 (1%)	1 (0%)
FEELING ABNORMAL	0 (0%)	1 (1%)	0 (0%)	1 (0%)
FEELING COLD	0 (0%)	1 (1%)	0 (0%)	1 (0%)
INFLAMMATION	0 (0%)	0 (0%)	1 (1%)	1 (0%)
SECRETION DISCHARGE	0 (0%)	0 (0%)	1 (1%)	1 (0%)
SUDDEN DEATH	0 (0%)	0 (0%)	1 (1%)	1 (0%)
SWELLING	0 (0%)	0 (0%)	1 (1%)	1 (0%)
ULCER	0 (0%)	0 (0%)	1 (1%)	1 (0%)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	**20 (23%)**	**39 (54%)**	**39 (41%)**	**98 (39%)**
PRURITUS	8 (9%)	25 (35%)	21 (22%)	54 (21%)

[1] † Denominator = all subjects per arm in ADSL (safety population).

TEAE: Treatment-Emergent Adverse Event (TRTEMFL = 'Y'). A subject is counted once per SOC/PT even if multiple events were reported. SOCs and preferred terms sorted by descending overall frequency.

Summary of Treatment-Emergent Adverse Events (TEAEs)

Number (%) of Unique Subjects with ≥ 1 TEAE, by SOC and Preferred Term

Primary System Organ Class Reported Term for the Adverse Event	Placebo N = 86[†1]	Xanomeline High Dose N = 72[†1]	Xanomeline Low Dose N = 96[†1]	Total N = 254[†1]
ERYTHEMA	8 (9%)	14 (19%)	14 (15%)	36 (14%)
RASH	5 (6%)	8 (11%)	13 (14%)	26 (10%)
HYPERHIDROSIS	2 (2%)	8 (11%)	4 (4%)	14 (6%)
SKIN IRRITATION	3 (3%)	5 (7%)	6 (6%)	14 (6%)
BLISTER	0 (0%)	1 (1%)	5 (5%)	6 (2%)
RASH PRURITIC	0 (0%)	2 (3%)	1 (1%)	3 (1%)
PRURITUS GENERALISED	0 (0%)	1 (1%)	1 (1%)	2 (1%)
URTICARIA	0 (0%)	1 (1%)	1 (1%)	2 (1%)
ACTINIC KERATOSIS	0 (0%)	1 (1%)	0 (0%)	1 (0%)
ALOPECIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)
COLD SWEAT	1 (1%)	0 (0%)	0 (0%)	1 (0%)
DERMATITIS CONTACT	0 (0%)	0 (0%)	1 (1%)	1 (0%)
DRUG ERUPTION	1 (1%)	0 (0%)	0 (0%)	1 (0%)
RASH ERYTHEMATOUS	0 (0%)	0 (0%)	1 (1%)	1 (0%)
RASH MACULO-PAPULAR	0 (0%)	1 (1%)	0 (0%)	1 (0%)
SKIN EXFOLIATION	0 (0%)	0 (0%)	1 (1%)	1 (0%)
SKIN ODOUR ABNORMAL	0 (0%)	1 (1%)	0 (0%)	1 (0%)
SKIN ULCER	1 (1%)	0 (0%)	0 (0%)	1 (0%)
NERVOUS SYSTEM DISORDERS	**8 (9%)**	**23 (32%)**	**22 (23%)**	**53 (21%)**

[1] † Denominator = all subjects per arm in ADSL (safety population).

TEAE: Treatment-Emergent Adverse Event (TRTEMFL = 'Y'). A subject is counted once per SOC/PT even if multiple events were reported. SOCs and preferred terms sorted by descending overall frequency.

Summary of Treatment-Emergent Adverse Events (TEAEs)

Number (%) of Unique Subjects with ≥ 1 TEAE, by SOC and Preferred Term

Primary System Organ Class Reported Term for the Adverse Event	Placebo N = 86[†1]	Xanomeline High Dose N = 72[†1]	Xanomeline Low Dose N = 96[†1]	Total N = 254[†1]
DIZZINESS	2 (2%)	10 (14%)	9 (9%)	21 (8%)
HEADACHE	3 (3%)	5 (7%)	3 (3%)	11 (4%)
SYNCOPE	0 (0%)	2 (3%)	5 (5%)	7 (3%)
SOMNOLENCE	2 (2%)	1 (1%)	3 (3%)	6 (2%)
TRANSIENT ISCHAEMIC ATTACK	0 (0%)	1 (1%)	2 (2%)	3 (1%)
BURNING SENSATION	0 (0%)	2 (3%)	0 (0%)	2 (1%)
LETHARGY	0 (0%)	1 (1%)	1 (1%)	2 (1%)
AMNESIA	0 (0%)	1 (1%)	0 (0%)	1 (0%)
BALANCE DISORDER	0 (0%)	0 (0%)	1 (1%)	1 (0%)
COGNITIVE DISORDER	0 (0%)	1 (1%)	0 (0%)	1 (0%)
COMPLEX PARTIAL SEIZURES	0 (0%)	0 (0%)	1 (1%)	1 (0%)
COORDINATION ABNORMAL	0 (0%)	0 (0%)	1 (1%)	1 (0%)
HEMIANOPIA HOMONYMOUS	0 (0%)	0 (0%)	1 (1%)	1 (0%)
HYPERSOMNIA	0 (0%)	1 (1%)	0 (0%)	1 (0%)
PARAESTHESIA	0 (0%)	1 (1%)	0 (0%)	1 (0%)
PARAESTHESIA ORAL	0 (0%)	0 (0%)	1 (1%)	1 (0%)
PARKINSON'S DISEASE	1 (1%)	0 (0%)	0 (0%)	1 (0%)
PAROSMIA	0 (0%)	1 (1%)	0 (0%)	1 (0%)
PARTIAL SEIZURES WITH SECONDARY GENERALISATION	0 (0%)	1 (1%)	0 (0%)	1 (0%)
PSYCHOMOTOR HYPERACTIVITY	1 (1%)	0 (0%)	0 (0%)	1 (0%)
STUPOR	0 (0%)	0 (0%)	1 (1%)	1 (0%)

[1] † Denominator = all subjects per arm in ADSL (safety population).

TEAE: Treatment-Emergent Adverse Event (TRTEMFL = 'Y'). A subject is counted once per SOC/PT even if multiple events were reported. SOCs and preferred terms sorted by descending overall frequency.

Summary of Treatment-Emergent Adverse Events (TEAEs)

Number (%) of Unique Subjects with ≥ 1 TEAE, by SOC and Preferred Term

Primary System Organ Class Reported Term for the Adverse Event	Placebo N = 86[†1]	Xanomeline High Dose N = 72[†1]	Xanomeline Low Dose N = 96[†1]	Total N = 254[†1]
SYNCOPE VASOVAGAL	0 (0%)	1 (1%)	0 (0%)	1 (0%)
GASTROINTESTINAL DISORDERS	**17 (20%)**	**19 (26%)**	**15 (16%)**	**51 (20%)**
DIARRHOEA	9 (10%)	3 (4%)	5 (5%)	17 (7%)
VOMITING	3 (3%)	6 (8%)	4 (4%)	13 (5%)
NAUSEA	3 (3%)	6 (8%)	3 (3%)	12 (5%)
ABDOMINAL PAIN	1 (1%)	1 (1%)	3 (3%)	5 (2%)
SALIVARY HYPERSECRETION	0 (0%)	4 (6%)	0 (0%)	4 (2%)
DYSPEPSIA	1 (1%)	0 (0%)	1 (1%)	2 (1%)
ABDOMINAL DISCOMFORT	0 (0%)	1 (1%)	0 (0%)	1 (0%)
CONSTIPATION	1 (1%)	0 (0%)	0 (0%)	1 (0%)
DYSPHAGIA	0 (0%)	0 (0%)	1 (1%)	1 (0%)
FLATULENCE	1 (1%)	0 (0%)	0 (0%)	1 (0%)
GASTROINTESTINAL HAEMORRHAGE	0 (0%)	1 (1%)	0 (0%)	1 (0%)
GASTROOESOPHAGEAL REFLUX DISEASE	1 (1%)	0 (0%)	0 (0%)	1 (0%)
GLOSSITIS	1 (1%)	0 (0%)	0 (0%)	1 (0%)
HIATUS HERNIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)
RECTAL HAEMORRHAGE	0 (0%)	0 (0%)	1 (1%)	1 (0%)
STOMACH DISCOMFORT	0 (0%)	1 (1%)	0 (0%)	1 (0%)
CARDIAC DISORDERS	**12 (14%)**	**14 (19%)**	**14 (15%)**	**40 (16%)**

[1] † Denominator = all subjects per arm in ADSL (safety population).

TEAE: Treatment-Emergent Adverse Event (TRTEMFL = 'Y'). A subject is counted once per SOC/PT even if multiple events were reported. SOCs and preferred terms sorted by descending overall frequency.

Summary of Treatment-Emergent Adverse Events (TEAEs)

Number (%) of Unique Subjects with ≥ 1 TEAE, by SOC and Preferred Term

Primary System Organ Class Reported Term for the Adverse Event	Placebo N = 86[†1]	Xanomeline High Dose N = 72[†1]	Xanomeline Low Dose N = 96[†1]	Total N = 254[†1]
SINUS BRADYCARDIA	2 (2%)	8 (11%)	7 (7%)	17 (7%)
MYOCARDIAL INFARCTION	4 (5%)	4 (6%)	2 (2%)	10 (4%)
ATRIAL FIBRILLATION	1 (1%)	2 (3%)	2 (2%)	5 (2%)
SUPRAVENTRICULAR EXTRASYSTOLES	1 (1%)	1 (1%)	1 (1%)	3 (1%)
VENTRICULAR EXTRASYSTOLES	0 (0%)	1 (1%)	2 (2%)	3 (1%)
ATRIAL FLUTTER	0 (0%)	1 (1%)	1 (1%)	2 (1%)
ATRIOVENTRICULAR BLOCK FIRST DEGREE	1 (1%)	0 (0%)	1 (1%)	2 (1%)
BUNDLE BRANCH BLOCK RIGHT	1 (1%)	0 (0%)	1 (1%)	2 (1%)
PALPITATIONS	0 (0%)	0 (0%)	2 (2%)	2 (1%)
ATRIAL HYPERTROPHY	1 (1%)	0 (0%)	0 (0%)	1 (0%)
ATRIOVENTRICULAR BLOCK SECOND DEGREE	1 (1%)	0 (0%)	0 (0%)	1 (0%)
BRADYCARDIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)
BUNDLE BRANCH BLOCK LEFT	1 (1%)	0 (0%)	0 (0%)	1 (0%)
CARDIAC DISORDER	0 (0%)	1 (1%)	0 (0%)	1 (0%)
CARDIAC FAILURE CONGESTIVE	1 (1%)	0 (0%)	0 (0%)	1 (0%)
SINUS ARRHYTHMIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)
SUPRAVENTRICULAR TACHYCARDIA	0 (0%)	0 (0%)	1 (1%)	1 (0%)
TACHYCARDIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)
VENTRICULAR HYPERTROPHY	1 (1%)	0 (0%)	0 (0%)	1 (0%)
WOLFF-PARKINSON-WHITE SYNDROME	0 (0%)	0 (0%)	1 (1%)	1 (0%)

[1] † Denominator = all subjects per arm in ADSL (safety population).

TEAE: Treatment-Emergent Adverse Event (TRTEMFL = 'Y'). A subject is counted once per SOC/PT even if multiple events were reported. SOCs and preferred terms sorted by descending overall frequency.

Summary of Treatment-Emergent Adverse Events (TEAEs)

Number (%) of Unique Subjects with ≥ 1 TEAE, by SOC and Preferred Term

Primary System Organ Class Reported Term for the Adverse Event	Placebo N = 86[†1]	Xanomeline High Dose N = 72[†1]	Xanomeline Low Dose N = 96[†1]	Total N = 254[†1]
INFECTIONS AND INFESTATIONS	**16 (19%)**	**13 (18%)**	**9 (9%)**	**38 (15%)**
NASOPHARYNGITIS	2 (2%)	6 (8%)	4 (4%)	12 (5%)
UPPER RESPIRATORY TRACT INFECTION	6 (7%)	3 (4%)	1 (1%)	10 (4%)
INFLUENZA	1 (1%)	1 (1%)	1 (1%)	3 (1%)
URINARY TRACT INFECTION	2 (2%)	1 (1%)	0 (0%)	3 (1%)
CYSTITIS	1 (1%)	1 (1%)	0 (0%)	2 (1%)
EAR INFECTION	2 (2%)	0 (0%)	0 (0%)	2 (1%)
BRONCHITIS	1 (1%)	0 (0%)	0 (0%)	1 (0%)
CELLULITIS	0 (0%)	0 (0%)	1 (1%)	1 (0%)
CERVICITIS	1 (1%)	0 (0%)	0 (0%)	1 (0%)
GASTROENTERITIS VIRAL	1 (1%)	0 (0%)	0 (0%)	1 (0%)
HORDEOLUM	0 (0%)	1 (1%)	0 (0%)	1 (0%)
LOCALISED INFECTION	1 (1%)	0 (0%)	0 (0%)	1 (0%)
LOWER RESPIRATORY TRACT INFECTION	0 (0%)	1 (1%)	0 (0%)	1 (0%)
PNEUMONIA	0 (0%)	0 (0%)	1 (1%)	1 (0%)
RHINITIS	0 (0%)	1 (1%)	0 (0%)	1 (0%)
VAGINAL MYCOSIS	1 (1%)	0 (0%)	0 (0%)	1 (0%)
VIRAL INFECTION	0 (0%)	0 (0%)	1 (1%)	1 (0%)
PSYCHIATRIC DISORDERS	**10 (12%)**	**7 (10%)**	**11 (11%)**	**28 (11%)**
CONFUSIONAL STATE	2 (2%)	1 (1%)	3 (3%)	6 (2%)

[1] † Denominator = all subjects per arm in ADSL (safety population).

TEAE: Treatment-Emergent Adverse Event (TRTEMFL = 'Y'). A subject is counted once per SOC/PT even if multiple events were reported. SOCs and preferred terms sorted by descending overall frequency.

Summary of Treatment-Emergent Adverse Events (TEAEs)

Number (%) of Unique Subjects with ≥ 1 TEAE, by SOC and Preferred Term

Primary System Organ Class Reported Term for the Adverse Event	Placebo N = 86[†1]	Xanomeline High Dose N = 72[†1]	Xanomeline Low Dose N = 96[†1]	Total N = 254[†1]
AGITATION	2 (2%)	0 (0%)	3 (3%)	5 (2%)
INSOMNIA	2 (2%)	2 (3%)	0 (0%)	4 (2%)
ANXIETY	0 (0%)	0 (0%)	3 (3%)	3 (1%)
DELUSION	1 (1%)	1 (1%)	0 (0%)	2 (1%)
IRRITABILITY	1 (1%)	0 (0%)	1 (1%)	2 (1%)
COMPLETED SUICIDE	1 (1%)	0 (0%)	0 (0%)	1 (0%)
DELIRIUM	0 (0%)	1 (1%)	0 (0%)	1 (0%)
DEPRESSED MOOD	0 (0%)	0 (0%)	1 (1%)	1 (0%)
DISORIENTATION	1 (1%)	0 (0%)	0 (0%)	1 (0%)
HALLUCINATION	0 (0%)	1 (1%)	0 (0%)	1 (0%)
HALLUCINATION, VISUAL	0 (0%)	1 (1%)	0 (0%)	1 (0%)
LIBIDO DECREASED	0 (0%)	1 (1%)	0 (0%)	1 (0%)
LISTLESS	0 (0%)	1 (1%)	0 (0%)	1 (0%)
NIGHTMARE	0 (0%)	1 (1%)	0 (0%)	1 (0%)
RESTLESSNESS	0 (0%)	0 (0%)	1 (1%)	1 (0%)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	**8 (9%)**	**10 (14%)**	**9 (9%)**	**27 (11%)**
COUGH	1 (1%)	5 (7%)	5 (5%)	11 (4%)
NASAL CONGESTION	3 (3%)	3 (4%)	1 (1%)	7 (3%)
DYSPNOEA	1 (1%)	1 (1%)	1 (1%)	3 (1%)
EPISTAXIS	0 (0%)	2 (3%)	1 (1%)	3 (1%)
PHARYNGOLARYNGEAL PAIN	0 (0%)	1 (1%)	1 (1%)	2 (1%)

[1] † Denominator = all subjects per arm in ADSL (safety population).

TEAE: Treatment-Emergent Adverse Event (TRTEMFL = 'Y'). A subject is counted once per SOC/PT even if multiple events were reported. SOCs and preferred terms sorted by descending overall frequency.

Summary of Treatment-Emergent Adverse Events (TEAEs)

Number (%) of Unique Subjects with ≥ 1 TEAE, by SOC and Preferred Term

Primary System Organ Class Reported Term for the Adverse Event	Placebo N = 86[†1]	Xanomeline High Dose N = 72[†1]	Xanomeline Low Dose N = 96[†1]	Total N = 254[†1]
RHINORRHOEA	0 (0%)	1 (1%)	1 (1%)	2 (1%)
ALLERGIC GRANULOMATOUS ANGIITIS	0 (0%)	1 (1%)	0 (0%)	1 (0%)
DYSPHONIA	0 (0%)	0 (0%)	1 (1%)	1 (0%)
EMPHYSEMA	1 (1%)	0 (0%)	0 (0%)	1 (0%)
HAEMOPTYSIS	1 (1%)	0 (0%)	0 (0%)	1 (0%)
PHARYNGEAL ERYTHEMA	0 (0%)	1 (1%)	0 (0%)	1 (0%)
POSTNASAL DRIP	1 (1%)	0 (0%)	0 (0%)	1 (0%)
PRODUCTIVE COUGH	0 (0%)	1 (1%)	0 (0%)	1 (0%)
RALES	1 (1%)	0 (0%)	0 (0%)	1 (0%)
RESPIRATORY TRACT CONGESTION	0 (0%)	1 (1%)	0 (0%)	1 (0%)
INVESTIGATIONS	**10 (12%)**	**5 (7%)**	**7 (7%)**	**22 (9%)**
ELECTROCARDIOGRAM ST SEGMENT DEPRESSION	4 (5%)	0 (0%)	1 (1%)	5 (2%)
ELECTROCARDIOGRAM T WAVE INVERSION	2 (2%)	1 (1%)	1 (1%)	4 (2%)
BLOOD GLUCOSE INCREASED	0 (0%)	1 (1%)	1 (1%)	2 (1%)
ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED	1 (1%)	0 (0%)	1 (1%)	2 (1%)
BIOPSY	0 (0%)	1 (1%)	0 (0%)	1 (0%)
BIOPSY PROSTATE	0 (0%)	1 (1%)	0 (0%)	1 (0%)
BLOOD ALKALINE PHOSPHATASE INCREASED	1 (1%)	0 (0%)	0 (0%)	1 (0%)
BLOOD CHOLESTEROL INCREASED	0 (0%)	1 (1%)	0 (0%)	1 (0%)
BLOOD CREATINE PHOSPHOKINASE INCREASED	1 (1%)	0 (0%)	0 (0%)	1 (0%)

[1] † Denominator = all subjects per arm in ADSL (safety population).

TEAE: Treatment-Emergent Adverse Event (TRTEMFL = 'Y'). A subject is counted once per SOC/PT even if multiple events were reported. SOCs and preferred terms sorted by descending overall frequency.

Summary of Treatment-Emergent Adverse Events (TEAEs)

Number (%) of Unique Subjects with ≥ 1 TEAE, by SOC and Preferred Term

Primary System Organ Class Reported Term for the Adverse Event	Placebo N = 86[†1]	Xanomeline High Dose N = 72[†1]	Xanomeline Low Dose N = 96[†1]	Total N = 254[†1]
BLOOD URINE PRESENT	1 (1%)	0 (0%)	0 (0%)	1 (0%)
BODY TEMPERATURE INCREASED	0 (0%)	0 (0%)	1 (1%)	1 (0%)
CYSTOSCOPY	1 (1%)	0 (0%)	0 (0%)	1 (0%)
HEART RATE INCREASED	1 (1%)	0 (0%)	0 (0%)	1 (0%)
HEART RATE IRREGULAR	1 (1%)	0 (0%)	0 (0%)	1 (0%)
NASAL MUCOSA BIOPSY	0 (0%)	0 (0%)	1 (1%)	1 (0%)
WEIGHT DECREASED	0 (0%)	0 (0%)	1 (1%)	1 (0%)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	**4 (5%)**	**7 (10%)**	**7 (7%)**	**18 (7%)**
BACK PAIN	1 (1%)	3 (4%)	1 (1%)	5 (2%)
ARTHRALGIA	1 (1%)	1 (1%)	2 (2%)	4 (2%)
SHOULDER PAIN	1 (1%)	0 (0%)	2 (2%)	3 (1%)
MUSCLE SPASMS	0 (0%)	1 (1%)	1 (1%)	2 (1%)
ARTHRITIS	0 (0%)	1 (1%)	0 (0%)	1 (0%)
FLANK PAIN	0 (0%)	1 (1%)	0 (0%)	1 (0%)
MUSCULAR WEAKNESS	0 (0%)	0 (0%)	1 (1%)	1 (0%)
MYALGIA	0 (0%)	1 (1%)	0 (0%)	1 (0%)
PAIN IN EXTREMITY	1 (1%)	0 (0%)	0 (0%)	1 (0%)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	**4 (5%)**	**5 (7%)**	**5 (5%)**	**14 (6%)**
CONTUSION	1 (1%)	2 (3%)	1 (1%)	4 (2%)
EXCORIATION	2 (2%)	1 (1%)	1 (1%)	4 (2%)
FALL	1 (1%)	1 (1%)	2 (2%)	4 (2%)

[1] † Denominator = all subjects per arm in ADSL (safety population).

TEAE: Treatment-Emergent Adverse Event (TRTEMFL = 'Y'). A subject is counted once per SOC/PT even if multiple events were reported. SOCs and preferred terms sorted by descending overall frequency.

Summary of Treatment-Emergent Adverse Events (TEAEs)

Number (%) of Unique Subjects with ≥ 1 TEAE, by SOC and Preferred Term

Primary System Organ Class Reported Term for the Adverse Event	Placebo N = 86[†1]	Xanomeline High Dose N = 72[†1]	Xanomeline Low Dose N = 96[†1]	Total N = 254[†1]
HIP FRACTURE	1 (1%)	2 (3%)	0 (0%)	3 (1%)
SKIN LACERATION	1 (1%)	0 (0%)	2 (2%)	3 (1%)
FACIAL BONES FRACTURE	0 (0%)	1 (1%)	0 (0%)	1 (0%)
JOINT DISLOCATION	0 (0%)	0 (0%)	1 (1%)	1 (0%)
WOUND	0 (0%)	0 (0%)	1 (1%)	1 (0%)
RENAL AND URINARY DISORDERS	**4 (5%)**	**3 (4%)**	**3 (3%)**	**10 (4%)**
MICTURITION URGENCY	1 (1%)	1 (1%)	1 (1%)	3 (1%)
DYSURIA	1 (1%)	0 (0%)	1 (1%)	2 (1%)
NEPHROLITHIASIS	1 (1%)	1 (1%)	0 (0%)	2 (1%)
CALCULUS URETHRAL	0 (0%)	1 (1%)	0 (0%)	1 (0%)
INCONTINENCE	0 (0%)	0 (0%)	1 (1%)	1 (0%)
POLLAKIURIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)
METABOLISM AND NUTRITION DISORDERS	**6 (7%)**	**2 (3%)**	**1 (1%)**	**9 (4%)**
DECREASED APPETITE	1 (1%)	1 (1%)	0 (0%)	2 (1%)
FOOD CRAVING	1 (1%)	0 (0%)	1 (1%)	2 (1%)
INCREASED APPETITE	1 (1%)	1 (1%)	0 (0%)	2 (1%)
DEHYDRATION	1 (1%)	0 (0%)	0 (0%)	1 (0%)
DIABETES MELLITUS	1 (1%)	0 (0%)	0 (0%)	1 (0%)
HYPONATRAEMIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)
VASCULAR DISORDERS	**3 (3%)**	**1 (1%)**	**3 (3%)**	**7 (3%)**
HYPOTENSION	2 (2%)	0 (0%)	1 (1%)	3 (1%)

[1] † Denominator = all subjects per arm in ADSL (safety population).

TEAE: Treatment-Emergent Adverse Event (TRTEMFL = 'Y'). A subject is counted once per SOC/PT even if multiple events were reported. SOCs and preferred terms sorted by descending overall frequency.

Summary of Treatment-Emergent Adverse Events (TEAEs)

Number (%) of Unique Subjects with ≥ 1 TEAE, by SOC and Preferred Term

Primary System Organ Class Reported Term for the Adverse Event	Placebo N = 86[†1]	Xanomeline High Dose N = 72[†1]	Xanomeline Low Dose N = 96[†1]	Total N = 254[†1]
HYPERTENSION	1 (1%)	0 (0%)	1 (1%)	2 (1%)
HOT FLUSH	0 (0%)	0 (0%)	1 (1%)	1 (0%)
ORTHOSTATIC HYPOTENSION	1 (1%)	0 (0%)	0 (0%)	1 (0%)
WOUND HAEMORRHAGE	0 (0%)	1 (1%)	0 (0%)	1 (0%)
EYE DISORDERS	**2 (2%)**	**1 (1%)**	**2 (2%)**	**5 (2%)**
VISION BLURRED	0 (0%)	1 (1%)	1 (1%)	2 (1%)
CONJUNCTIVAL HAEMORRHAGE	0 (0%)	0 (0%)	1 (1%)	1 (0%)
CONJUNCTIVITIS	1 (1%)	0 (0%)	0 (0%)	1 (0%)
EYE ALLERGY	1 (1%)	0 (0%)	0 (0%)	1 (0%)
EYE PRURITUS	1 (1%)	0 (0%)	0 (0%)	1 (0%)
EYE SWELLING	1 (1%)	0 (0%)	0 (0%)	1 (0%)
SURGICAL AND MEDICAL PROCEDURES	**2 (2%)**	**2 (3%)**	**1 (1%)**	**5 (2%)**
CATARACT OPERATION	1 (1%)	0 (0%)	1 (1%)	2 (1%)
ACROCHORDON EXCISION	0 (0%)	1 (1%)	0 (0%)	1 (0%)
EYE LASER SURGERY	1 (1%)	0 (0%)	0 (0%)	1 (0%)
SKIN LESION EXCISION	0 (0%)	1 (1%)	0 (0%)	1 (0%)
EAR AND LABYRINTH DISORDERS	**1 (1%)**	**1 (1%)**	**2 (2%)**	**4 (2%)**
VERTIGO	0 (0%)	1 (1%)	1 (1%)	2 (1%)
CERUMEN IMPACTION	0 (0%)	0 (0%)	1 (1%)	1 (0%)
EAR PAIN	1 (1%)	0 (0%)	0 (0%)	1 (0%)
CONGENITAL, FAMILIAL AND GENETIC DISORDERS	**0 (0%)**	**2 (3%)**	**1 (1%)**	**3 (1%)**

[1] † Denominator = all subjects per arm in ADSL (safety population).

TEAE: Treatment-Emergent Adverse Event (TRTEMFL = 'Y'). A subject is counted once per SOC/PT even if multiple events were reported. SOCs and preferred terms sorted by descending overall frequency.

Summary of Treatment-Emergent Adverse Events (TEAEs)

Number (%) of Unique Subjects with ≥ 1 TEAE, by SOC and Preferred Term

Primary System Organ Class Reported Term for the Adverse Event	Placebo N = 86[†1]	Xanomeline High Dose N = 72[†1]	Xanomeline Low Dose N = 96[†1]	Total N = 254[†1]
VENTRICULAR SEPTAL DEFECT	0 (0%)	2 (3%)	1 (1%)	3 (1%)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	**0 (0%)**	**1 (1%)**	**2 (2%)**	**3 (1%)**
COLON CANCER	0 (0%)	0 (0%)	1 (1%)	1 (0%)
MALIGNANT FIBROUS HISTIOCYTOMA	0 (0%)	0 (0%)	1 (1%)	1 (0%)
PROSTATE CANCER	0 (0%)	1 (1%)	0 (0%)	1 (0%)
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	**2 (2%)**	**1 (1%)**	**0 (0%)**	**3 (1%)**
BENIGN PROSTATIC HYPERPLASIA	1 (1%)	1 (1%)	0 (0%)	2 (1%)
PELVIC PAIN	1 (1%)	0 (0%)	0 (0%)	1 (0%)
HEPATOBILIARY DISORDERS	**1 (1%)**	**0 (0%)**	**0 (0%)**	**1 (0%)**
HYPERBILIRUBINAEMIA	1 (1%)	0 (0%)	0 (0%)	1 (0%)
IMMUNE SYSTEM DISORDERS	**0 (0%)**	**0 (0%)**	**1 (1%)**	**1 (0%)**
HYPERSENSITIVITY	0 (0%)	0 (0%)	1 (1%)	1 (0%)
SOCIAL CIRCUMSTANCES	**0 (0%)**	**1 (1%)**	**0 (0%)**	**1 (0%)**
ALCOHOL USE	0 (0%)	1 (1%)	0 (0%)	1 (0%)

[1] † Denominator = all subjects per arm in ADSL (safety population).

TEAE: Treatment-Emergent Adverse Event (TRTEMFL = 'Y'). A subject is counted once per SOC/PT even if multiple events were reported. SOCs and preferred terms sorted by descending overall frequency.